Oculis Holding AG

詳細情報 Oculis Holding AG 企業名

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

企業情報

企業コードOCS

会社名Oculis Holding AG

上場日Mar 03, 2023

最高経営責任者「CEO」Dr. Riad Sherif, M.D.

従業員数49

証券種類Ordinary Share

決算期末Mar 03

本社所在地Bahnhofstrasse 20

都市ZUG

証券取引所NASDAQ Global Market Consolidated

国Switzerland

郵便番号6300

電話番号41417113960

ウェブサイトhttps://oculis.com/

企業コードOCS

上場日Mar 03, 2023

最高経営責任者「CEO」Dr. Riad Sherif, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dhr. Martijn Kleijwegt ,

Independent Director

470.97K

--

Mr. Pall Ragnar Johannesson

Chief Strategy Officer

268.83K

+7.87%

Ms. Sylvia Cheung, CPA

Chief Financial Officer

72.06K

+7.86%

Ms. Geraldine O'Keeffe

Independent Director

20.59K

--

Dr. Bastian Dehmel, M.D.

Head - Development

--

Mr. Anthony A. (Tony) Rosenberg

Independent Chairman of the Board

--

Dr. Riad Sherif, M.D.

Chief Executive Officer, Director

--

Ms. Christina M. Ackermann

Independent Director

--

-100.00%

Mr. Lionel Carnot

Independent Director

--

Dr. Pravin U. Dugel, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dhr. Martijn Kleijwegt ,

Independent Director

470.97K

--

Mr. Pall Ragnar Johannesson

Chief Strategy Officer

268.83K

+7.87%

Ms. Sylvia Cheung, CPA

Chief Financial Officer

72.06K

+7.86%

Ms. Geraldine O'Keeffe

Independent Director

20.59K

--

Dr. Bastian Dehmel, M.D.

Head - Development

--

Mr. Anthony A. (Tony) Rosenberg

Independent Chairman of the Board

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Mon, Sep 8

株主統計

種類

株主統計

比率

EQT Life Sciences

10.99%

Earlybird Venture Capital

4.86%

Pivotal Bioventure Partners Investment Advisor LLC

4.40%

BVCF Management, Ltd.

4.19%

Novartis AG

3.27%

他の

72.29%

株主統計

比率

EQT Life Sciences

10.99%

Earlybird Venture Capital

4.86%

Pivotal Bioventure Partners Investment Advisor LLC

4.40%

BVCF Management, Ltd.

4.19%

Novartis AG

3.27%

他の

72.29%

種類

株主統計

比率

Venture Capital

26.04%

Corporation

3.27%

Individual Investor

3.04%

Investment Advisor/Hedge Fund

2.64%

Investment Advisor

1.85%

Hedge Fund

0.55%

Research Firm

0.09%

Bank and Trust

0.04%

Pension Fund

0.04%

他の

62.44%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

51

19.48M

37.42%

+1.76M

2025Q1

51

19.44M

37.35%

+1.93M

2024Q4

86

15.00M

31.97%

-10.87M

2024Q3

87

16.29M

41.43%

-9.17M

2024Q2

88

16.63M

42.28%

-9.14M

2024Q1

91

16.14M

42.22%

-11.25M

2023Q4

93

17.20M

46.87%

-6.97M

2023Q3

92

16.51M

48.34%

-4.37M

2023Q2

91

16.72M

48.91%

-4.14M

2023Q1

88

16.73M

51.20%

+4.73M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

EQT Life Sciences

5.75M

11.05%

+425.53K

+7.99%

Dec 31, 2024

Earlybird Venture Capital

2.54M

4.89%

+2.54M

--

Dec 31, 2024

Pivotal Bioventure Partners Investment Advisor LLC

2.30M

4.42%

+563.08K

+32.40%

Mar 31, 2025

BVCF Management, Ltd.

2.19M

4.21%

+121.79K

+5.88%

Nov 27, 2024

Novartis AG

1.71M

3.29%

-464.38K

-21.32%

Feb 13, 2024

abrdn Inc.

1.25M

2.41%

+243.69K

+24.14%

Mar 31, 2025

Sherif (Riad M.D.)

644.75K

1.24%

-233.73K

-26.61%

Dec 31, 2024

Stefnir hf.

510.50K

0.98%

--

May 31, 2025

Nan Fung Life Sciences

514.70K

0.99%

+78.32K

+17.95%

Mar 31, 2025

Kleijwegt (Martijn)

470.97K

0.9%

+470.97K

--

Dec 31, 2024

詳細を見る

17.400USD

Oculis Holding AG

17.400

概要

企業名

金融

分析